All News

Article

ACR21 – Day 3 Report

Jack Cush, MD

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Akhil Sood MD Tweet
AkhilSoodMD
Abst 1517 Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE - Most common rheumatic IRAE = inflammatory arthritis - Higher prevalence of ANA in those tx w/ chemo prior to ICI #ACR21 @RheumNow https://t.co/7qgogSMjUr
David Liew Tweet
drdavidliew
STAR-RA, CV risk large insurance datax3 tofa vs TNFi all comers: HR 1.01 (0.83-1.23) one CV RF + any MTX: HR 1.24 (0.90-1.69) prev CVD: HR 1.27 (0.95-1.70) not sig but surely okay to say baseline CV risk + tofa makes me a little nervous? @SeoyoungCKim #ACR21 ABST1939 @RheumNow https://t.co/LmmL5zgv9u
Aurelie Najm Tweet
AurelieRheumo
Another study linking long term GC and CV risk in RA! Medicare data >65yo 130000+ pts 1-year incidence CV ⬆️ as follows: 📍Dose ≤5mg 1.4% 📍Dose 5-10mg 1.7% 📍Dose >10mg 1.9% Not replicated in younger pts (Optum data) #ACR21 #Abst1915 @RheumNow https://t.co/DLXdfvfiBW
Mrinalini Dey Tweet
DrMiniDey
#ACR21 Abs#1915 👉🏼Chronic steroid use in older adults on stable DMARD therapy assoc w/ ⬆️CV risk 👉🏼Risk even present among older adults receiving low dose ≤5mg/day 👉🏼Larger studies needed in younger healthier adults @RheumNow https://t.co/Lsj5YBz7IG
Richard Conway Tweet
RichardPAConway
Long-term low dose glucocorticoid use associated ⬆️cardiovascular risk. Clear effect in Medicare population (older), not evident in Optum (younger). Dose dependent. Abstr#1915 #ACR21 @RheumNow https://t.co/oFet3Hhsfo
Mike Putman Tweet
EBRheum
Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA RTX not superior to CYC (64% RTX vs 60% CYC BVAS remission d180, p = 0.745); similar in subgroups Feel like this lends support to (~surprising) ACR/VF recs for EGPA? #ACR21 #ACRAmbassador https://t.co/gpsPtXF6pj
sheila Tweet
RHEUMarampa
Post hoc analysis of pooled data from 19 clin trials on SEC & CV risk & systemic #inflammation in PsO, PsA, AS 📌Traditional CV parameters remained stable on all SEC treated grps 📌SEC sig. ⬇hsCRP & NLR @RheumNow #ACR21 abs1835 https://t.co/iCaGFbXNXn
David Liew Tweet
drdavidliew
b/tsDMARDs + tumor response in rheum irAEs Excellent point by @CCalabreseDO @LCalabreseDO: - despite progression in 5/10, DMARD contribution uncertain (bad cancer) - without DMARD, ICI would have had to stop crucial question, prospective study needed #ACR21 ABST1519 @RheumNow https://t.co/omJnTNVscH
David Liew Tweet
drdavidliew
Autoantibodies are underrated in rheumatic irAEs (?B cells in general), but probably not your usual. If Ab are of interest, suspect we're going to have to look at non-classical ones Elegant from @NilashaGhosh @MPostow @got_rheum @lovetolearn27 #ACR21 ABST1520 ABST1521 @RheumNow https://t.co/tLSJOZw1YG
David Liew Tweet
drdavidliew
For patients with inflammatory irAEs, what's your preference of bDMARD/tsDMARD? (keeping in mind both irAE response and tumor response) #ACR21 irAE Study Group run by @CCalabreseDO @NAbdelwahabMD @ReidMDMPH @RheumNow
Mrinalini Dey Tweet
DrMiniDey
Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis 👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA 👉🏼No new safety risks with long-term use 👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r
Eric Dein Tweet
ericdeinmd
#ACR21 Ab#1681: ATI-450- MK2 Inhibitor ⭐️Downstream MK2 mediated inflamm drive of p38. ⭐️Hope this would avoid tachyphylaxis in p38 inhibitor meds ▶️Phase2a study in 19 pts: Well-tolerated (SEs: UTI, ventricular extrasystole), good 12 week data @Rheumnow https://t.co/6lo7zPJUpx
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×